Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1198-1205

  Taguchi, Fumiko ^a   Kodera, Yasuo ^a   Katanasaka, Yasufumi ^a   Yanagihara, Kazuyoshi ^b   Tamura, Tomohide ^a   Koizumi, Fumiaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b YASUDA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Everolimus; Gastric cancer; Hypoxia; Peritoneal dissemination

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; S6 KINASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DISSEMINATED CANCER; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PERITONEUM CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL HYPOXIA; METABOLISM; NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, SCIRRHOUS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PERITONEAL NEOPLASMS; PHOSPHORYLATION; SIROLIMUS; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84856037018     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9464-9     Document Type: Article

References (32)

1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59
2. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657 (Pubitemid 30465650)
3. Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1-11 (Pubitemid 12136698)
4. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22:2069-2077 (Pubitemid 41095139)
5. Yamada E, Miyaishi S, Nakazato H, Kato K, Kito T, Takagi H, Yasue M, Kato T, Morimoto T, Yamauchi M (1980) The surgical treatment of cancer of the stomach. Int Surg 65:387-399 (Pubitemid 12115232)
6. Haraguchi M, Watanabe A, Kakeji Y, Tsujitani S, Baba H, Maehara Y, Sugimachi K (1991) Prognostic significance of serosal invasion in carcinoma of the stomach. Surg Gynecol Obstet 172:29-32
7. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M (1992) Pathology and prognosis of gastric carcinoma. Findings in 10, 000 patients who underwent primary gastrectomy. Cancer 70:1030-1037
8. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T (2003) Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 12:635-648 (Pubitemid 36920090)
9. Shimada K, Ajani JA (1999) Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer 86:1657-1668 (Pubitemid 29513033)
10. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148-159
11. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810 (Pubitemid 46399369)
12. Jiang H, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335 (Pubitemid 27516371)
13. Treins S Giorgetti-Peraldi, Murdaca J, Semenza GL, Van E (2002) Obberghen. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277:27975-27981 (Pubitemid 34966746)
14. Yoshikawa T, Tsuburaya A, Miyagi Y, Sekiguchi H, Kimura M, Cho H, Kobayashi O (2006) Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 26:3849-3853 (Pubitemid 44701470)
15. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348 (Pubitemid 38579480)
16. Boulay S, Zumstein-Mecker C, Stephan I, Beuvink F, Zilbermann R, Haller S, Tobler C, Heusser T, O'Reilly B, Stolz A, Marti G, Thomas H, Lane A (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative EVEROLIMUS correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261
17. Beuvink A, Boulay S, Fumagalli F, Zilbermann S, Ruetz T, O'Reilly F, Natt J, Hall H, Lane A, Thomas G (2005) The mTOR inhibitor EVEROLIMUS sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747-759 (Pubitemid 40568794)
18. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) EVEROLIMUS inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13:4261-4270 (Pubitemid 47105991)
19. Atkins MB, Yasothan U, Kirkpatrick P (2009) Everolimus. Nat Rev Drug Discov 8:535-536
20. Janssen HL, Haustermans KM, Balm AJ, Begg AC (2005) Hypoxia in head and neck cancer: how much, how important? Head Neck 27:622-638 (Pubitemid 40961072)
21. Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y, Toge T, Sugano K, Hirohashi S (2004) Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 95:575-582 (Pubitemid 39089638)
22. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S (2005) Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 96:323-332 (Pubitemid 41007466)
23. Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F, Ochiya T (2006) A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res 66:7532-7539 (Pubitemid 44289208)
24. Homicsko K, Lukashev A, Iggo RD (2005) EVEROLIMUS (Everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65:6882-6890 (Pubitemid 41060727)
25. Yashiro M, Chung YS, Nishimura S, Matsuoka T, Fujihara T, Sowa M (1996) Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer 67:289-293 (Pubitemid 26274163)
26. Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y, Nagashima Y, Miyagi Y, Mitsuhashi M, Hyndman D, Hoffman RM, Ohki S, Shimada H (2002) VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 9:197-201 (Pubitemid 34141923)
27. Lo SS, Wu CW, Chi CW, Li AF, Chen JH, Lui WY (2005) High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis. Hepatogastroenterology 52:1902-1904 (Pubitemid 41745657)
28. Yamada A, Saito N, Kameoka S, Kobayashi M (2007) Clinical significance of epidermal growth factor (EGF) expression in gastric cancer. Hepatogastroenterology 76:1049-1052 (Pubitemid 47013902)
29. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada K, Saiki I (2008) Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 44:1022-1029
30. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, Takahashi Y, Shibuya K, Hirota K, Semenza GL, Hiraoka M (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15:3433-4341
31. Arsham M, Howell JJ, Simon MC (2003) A novel hypoxiainducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278:29655-29660 (Pubitemid 36962350)
32. Hamanaka Y, Mukai M, Shimamura M, Kitagawa T, Nishida T, Isohashi F, Ito T, Nishizawa Y, Tatsuta M, Matsuda H, Inoue M (2005) Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia. Biochem Biophys Res Commun 330:318-326 (Pubitemid 40394969)